

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/15, C07K 14/18, A61K 38/55, C12N 15/62, A01H 5/00, C12N 1/21, A01N 33/16		A2	(11) International Publication Number: WO 96/16173 (43) International Publication Date: 30 May 1996 (30.05.96)
(21) International Application Number: PCT/GB95/02711 (22) International Filing Date: 20 November 1995 (20.11.95) (30) Priority Data: 9423477.0 21 November 1994 (21.11.94) GB 9423450.7 21 November 1994 (21.11.94) GB (71) Applicant (for all designated States except US): THE UNIVERSITY OF LEEDS [GB/GB]; Leeds LS2 9JT (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): ATKINSON, Howard, John [GB/GB]; 43 Sutherland Avenue, Leeds LS8 1BY (GB). McPHERSON, Michael, John [GB/GB]; 45 Henley Avenue, Thornhill, Dewsbury WF12 0LN (GB). URWIN, Peter, Edward [GB/GB]; 86 Swinnow Close, Bramley, Leeds LS13 4NF (GB). (74) Agent: WILLIAM, Jones; The Crescent, 54 Blossom Street, York, North Yorkshire YO2 2AP (GB).		(81) Designated States: AL, AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, LS, MW, SD, SZ, UG). Published <i>Without international search report and to be republished upon receipt of that report.</i>	
(54) Title: MODIFIED PROTEINASE INHIBITORS			
(57) Abstract <p>The invention relates to proteinase inhibitors and in particular cystatins which have been modified so as to enhance their effective or synthetically manufactured counterparts. The modification including either site-directed alterations in the structure of the protein and/or the production of hybrid molecules.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

MODIFIED PROTEINASE INHIBITORS

The invention relates to proteinase inhibitors and in particular novel proteinase inhibitors, methods for producing such inhibitors and products and processors including such inhibitors.

5 Proteinases are enzymes that break down proteins, their substrate specificity varies considerably and therefore does not form a basis for the purpose of classification. Rather, typically, these enzymes are classified according to the nature of the catalytic reaction that each undertakes. Thus proteinases are divided into four groups termed serine proteinases, cysteine proteinases,
10 aspartic proteinases and metalloproteinases. Serine proteinases and cysteine proteinases are both widespread and diverse and are found in both prokaryotic and eukaryotic organisms, including plants and animals. In contrast, aspartic proteinases seem to be found only in eukaryotic organisms. Since these enzymes are used to break down protein the origin and/or the location of the
15 enzymes determines whether they are beneficial or detrimental to a given organism. For example, where the enzymes are used by pathogens or parasites or pests they are typically used to break down host cell tissue and are therefore detrimental.

20 Pathogens, parasites or pests such as bacteria, fungi, plants, insects, nematode worms etc produce proteinases which break down host cell tissue to the detriment of the host.

For example, annual global crop losses caused by fungi exceed a thousand million pounds. The pathogen, *Botrytis cinerea* is of major economic importance because it causes disease in thirty crop plant species, with serious

losses incurred in the glass house, in viticulture and as a result of post-harvest disease of fruit and vegetables. This major pathogen can be overcome with fungicides but unfortunately, there are disadvantages associated with the use of fungicides in order to control it. These include a financial burden associated with use of the fungicide, the potential environmental hazard arising from the use of toxic fungicides, with attendant consumer concern, and major problems of pathogen resistance to fungicides. In addition, many fungicides are effective against only a limited range of pathogenic fungi.

The above disadvantages are also common to the use of synthetic agents manufactured against other pathogens, parasites or pests such as insects, or specific insects, bacteria or specific bacteria and other eukaryotic organisms including, but not limited to: protozoa such as amoebas, intestinal flagellates and ciliates, haemoflagellates, such as leishmania or trypanosomes, sporozoa, such as those responsible for malaria, arthropod-borne organisms; helminths such as trematodes or flukes, cestodea, acanthocephala, nematodes, trichuris, trichinella, hook worms, filariae, spiruroids; arthropods such as acarina or mites, ticks heteroptera, lice, flees, diptera such as disease-carrying flies including mosquitos, maggots and myiasis.

Inhibition of proteinases is known to occur naturally following pathogen infection. For example, it has been shown that following infection by *Phytophthora infestans* varieties of tomato able to resist the fungus show increased levels of proteinase inhibitors (1). This relationship between resistance and the capacity to produce proteinase inhibitors has been used to good effect in the control of pathogen, pests and parasitic diseases. For example, in the most relevant prior art known to the applicant, plant pests are controlled by recombinantly introducing a proteinase inhibitor, animal-derived

egg white cystatin, into a selected monocotyledon such as a cereal, forage or turf grass, or a dicotyledon such as a vegetable, tube, or sugar crop, (EP 0 348 348). Similarly, plant nematode pests have been controlled using a proteinase inhibitor, plant-derived cowpea trypsin inhibitor, which has been
5 recombinantly introduced into tobacco, tomato, cotton, oilseed rape, vegetable crop or ornamental plants (EP O 502 730). In addition, it has been suggested that proteinase inhibitors can be used as anti-parasitic proteins which ideally can be administered to a host species either in a medicament or a food (UK Patent Application No. 94 03819.7).

10 It is therefore known to use proteinase inhibitors to neutralise the effects of proteinases and so combat the effects of pathogens, parasites or pests. In particular, it is known to transgenically produce plants which are provided with a specific proteinase inhibitor, such as a cysteine proteinase inhibitor.

15 However, it is the object of the present invention to provide a modified proteinase inhibitor which has greater efficacy than that of its unmodified counterpart or the natural proteinase inhibitor; or alternatively to synthetically manufacture and improve a proteinase inhibitor so as to provide, in one embodiment a hybrid proteinase inhibitor.

20 In one aspect of our invention we have focused on the group of proteinase inhibitors known as cystatins. The protein sequences of approximately 25 cystatins are known. It is possible to undertake alignment studies of these sequences in order to provide a basis for identifying structural similarities. It has been suggested that there are sufficient differences between plant and animal cystatins to justify separate classification of the two, indeed, a
25 comparison of a plant cystatin, Oryzacystatin I Oc-I [DNA sequence structure

shown in Figure 3], and an animal cystatin, egg white cystatin, reveals a significant number of differences showing that overall amino acid conservation is not high. Moreover, there are significant differences in the binding properties of animal and plant cystatins. Thus the dissociation constant K_i varies, for example, egg white cystatin has a K_i of $5 \times 10^{-12} \text{M}$, whereas the plant cystatin, Oc-I, (derived from rice), has a K_i of $3 \times 10^{-8} \text{M}$.

Alignment data of a number of cystatins is shown in Figure 1. The amino acids are numbered 1-181. It can be seen that there is a conserved inhibitory site at alignment amino acids 100-104, represented by the motif QVVAG (or QLVAG). In addition, it can be seen that there is a conserved PW motif at alignment amino acids 160-161.

This conservation occurs in approximately two thirds of the known sequence structures and is thought from structural studies to be involved in the functioning of the protein and thus for inhibition of proteinases. However, some cystatins with low K_i values do not possess this PW motif therefore its importance in cystatin function is unclear.

Other works have recombinantly manufactured novel cystatins. For example, the human cysteine proteinase inhibitor cystatin C, which participates in the intracellular catabolism of proteins and peptides, in the proteolytic conversion of prohormones, in the extracellular degredation of collagen and in the penetration of normal tissues with malignant cells, has been altered. Workers have modified cystatin C so that one or more amino acids at positions 5-17, 55-59 and/or 68 have been replaced by other amino acids thus retaining the total 120 amino acids in the sequence structure. Modifications were undertaken in order to provide an animal-derived cystatin C considered to

have constant activity. (WO 88/09384).

5 We have found, surprisingly, that site-directed modification of a plant cystatin such as, for example, Oryzacystatin I (Oc-I) can improve its binding properties and thus improve the efficacy of the enzyme in inhibiting proteinases. The site-directed modification involves elimination of the amino acid aspartic acid at position 86 of the amino acid sequence structure of the plant cystatin, this elimination improves the K_i 13 fold, that is to $2.3 \times 10^{-9}M$. This modification is represented by elimination of aspartic acid (symbol D) at position 163 of the alignment amino acids shown in Figure 1.

10 Clearly, this improvement in plant cystatin K_i does not exceed animal cystatin K_i , and particularly egg white cystatin. However, there is growing concern about the liberal approach to cross species transgenics. That is to say the introduction into one species of genes wholly from another species, such as for example, the introduction into plants of human genes encoding human proteins and visa versa. Until our understanding of the consequences of genetic manipulation is complete it would seem prudent to err on the side of caution and thus adopt a more rational approach to genetic manipulation. Thus, plant breeders throughout the world would prefer to combat plant diseases using plant derived proteins, or alternatively, proteins which are significantly similar to plant proteins such that their structural, biochemical and physiological functions are either the same as, or substantially similar to, or consistent with, that of plant proteins. This latter category includes, but is not limited to hybrid molecules.

20

Further, many animal cystatins with lower K_i 's have several disulphide bonds which are not found in plant cystatins so far characterised. Therefore in

25

order to ensure correct protein folding it may be prudent to use at least partially a plant cystatin in plant systems. Thus, our site-directed modification of a plant proteinase inhibitor, and in particular a plant cystatin, and our hybrid proteinase inhibitor when including at least a part of a plant proteinase inhibitor have provided novel improved proteins for preferred, but not exclusive, use in plant systems.

It is of note that there is very little conservation in the alignment amino acid sequences shown in Figure 1 above alignment amino acid 104 and therefore this makes our observation all the more startling. Previous site-directed modification studies of cystatins were concentrated on the highly conserved QVVAG motif referred to above, but modification of this region was always detrimental (12).

It follows from the foregoing that it is an object of the invention to provide a novel proteinase inhibitor having improved efficacy at least in terms of its binding to a proteinase.

It is also a further object of the invention to provide a novel proteinase inhibitor, ideally having improved efficacy, but also comprising a hybrid molecule which preferably, but not exclusively, comprises a part of a proteinase inhibitor from a first species and a part of proteinase inhibitor from a second species.

It is a further object of the invention to provide products including the whole or a part of the novel protein, or the whole or a part of the DNA encoding same, and also uses for this novel protein and/or DNA.

According to a first aspect of the invention there is therefore provided a proteinase inhibitor modified or manufactured so that it is more effective at inhibiting a proteinase with which it interacts than its corresponding naturally occurring counterpart.

- 5 Ideally, said proteinase inhibitor binds more strongly to the proteinase.

Accordingly there is provided a synthetic proteinase inhibitor which has a K_i with at least a 10 times lower value than its natural counterpart. For instance a change in K_i from $3 \times 10^{-8} M$ to at least $3 \times 10^{-9} M$ represents such an improvement in K_i .

- 10 According to a second aspect of the invention there is provided a proteinase inhibitor including at least one site-directed amino acid deletion and/or substitution which lowers the K_i of the protein at least 10 fold.

- 15 Preferably the protein is a cystatin and ideally the site-directed deletion or substitution concerns deletion of either aspartic acid at position 86 of the amino acid sequence structure of Oc-I, or alternatively, deletion of aspartic acid at position 163 of the alignment amino acid sequence structure shown in Figure 1 of an aligned proteinase inhibitor such as a cystatin, or alternatively, deletion of its functional counterpart in related proteinase inhibitors or cystatins.

- 20 Alternatively, the site-directed modification concerns substitution of said aspartic acid at said position for an alternative amino acid which has counter properties having regard to the functional property of the eliminated aspartic acid.

According to a third aspect of the invention there is provided the whole or part of the DNA sequence structure shown in Figure 2 which DNA sequence structure encodes an example of a protein according to a first aspect of the invention.

5 All the proteins of the invention, or the corresponding DNA sequence structures have utility in combating diseases whose symptoms are at least partially caused by or characterised by proteinase production. Thus the novel proteins and corresponding DNA sequence structures can be used, directly or indirectly, to prevent, alleviate or mitigate such diseased conditions. For
10 example, a host organism suffering from a pathogenic, pest or parasitic condition involving protein breakdown via proteinases can be treated by receiving at least one protein of the invention. Treatment can be undertaken by applying the said protein of the invention directly to the diseased organism, for example, in the form of a chemical agent such as a pesticide,
15 fungicide etc. or a medicament, or alternatively, by introducing the genetic sequence structure for the said protein of the invention into the genome of the host organism and ensuring that the said inventive protein is expressed by the host organism which organism is then equipped to fight the disease.

20 In the foregoing paragraph any one or more of the proteins of the invention may be used as aforescribed. For example, a selected combination of the proteins of the invention, that is to say proteins including site-directed modifications and/or hybrid proteins may be used to counter the effects of any one or more proteinases.

Ideally the transformed organism is a plant.

According to a further aspect of the invention there is provided a method of conferring resistance to proteolytic damage comprising modifying or transforming a host organism so that it expresses the protein of the invention.

5 According to a yet further aspect of the invention there is provided a construct including a whole or part of the DNA sequence structure of the invention. Said construct may include a plasmid or a vector.

According to a yet further aspect of the invention there is provided use of the protein or DNA sequence structure of the invention as a medicament to combat proteolytic conditions ideally of a pathogenic, parasitic or pest nature.

10 According to a further aspect of the invention there is provided a composition effective against pathogenic, parasitic or pest diseases including the protein of the invention.

15 According to a yet further aspect of the invention there is provided a transgenic plant transformed with DNA encoding the protein of the invention, and ideally the DNA shown in Figure 2, which DNA is coupled to a suitable promoter sequence so that the protein of the invention can be expressed. Ideally, expression is either generally within the plant or in the locale of the pest, pathogen or parasite interaction with the plant. As examples reference 13 provides general methods for identifying promoters from the locale of a
20 pest, pathogen or parasite of a plant. Alternatively, or in addition expression may be selected so as to occur at a selected given point in time.

Preferably said transformed plant is a cereal crop, vegetable crop, oil crop,

sugar crop, forage or turf grass, fibre plant, herbalspice plant, fruit crop or indeed any decorative plant.

According to a yet further aspect of the invention there is provided a transformed organism, plant or otherwise, which includes DNA encoding the protein of the invention, and ideally the DNA shown in Figure 2, so that said
5 protein can be harvested for the purpose of providing sources thereof.

Preferably, said construct is provided with suitable promoters for ensuring expression of the protein of the invention.

According to a yet further aspect of the invention there is provided a method
10 for controlling a pathogen, parasite or pest comprising exposing said pathogen, parasite or pest to the protein of the invention.

According to a further aspect of the invention there is provided use of the protein of the invention to control a pathogen, parasite or pest.

According to a yet further aspect of the invention there is provided any one
15 or more of the primers shown in Table 2, or primers of similar nature having additions, deletions or modifications thereto which still enable the primers to function as described herein.

The modified proteinase inhibitors of the invention may also include novel combinations of proteinase inhibitors either derived from the same or
20 different kingdom, phylum, class, order, family, genus or species. For example, fraction(s) of animal-derived proteinase inhibitor may be combined with fraction(s) of plant-derived proteinase inhibitor, all or one or more of

which may or may not include the aforescribed modification to improve efficacy. Or alternatively, different sorts or types of plant proteinase inhibitors may be combined to provide a novel plant proteinase inhibitor, or alternatively, different sorts or types of animal proteinase inhibitors may be combined to provide a novel proteinase inhibitor, all or one of more of which may or may not include the aforescribed modification to improve efficacy.

According to a yet further still aspect of the invention there is provided a protein and/or sequence of DNA comprising a first part from a first proteinase inhibitor and at least one other part from at least one other proteinase inhibitor.

In a preferred embodiment of the invention the DNA sequence of the further still aspect of the invention is provided in a construct so that a corresponding protein can be produced in target tissue such as host cell tissue.

According to a yet further aspect of the invention there is provided target tissue or host cell tissue transformed with the DNA sequence structure of the further still aspect of the invention.

According to a yet further aspect of the invention there is provided a protein comprising a first part from a first cystatin and at least one other part from at least one other cystatin.

In a preferred embodiment said first part of said DNA sequence or said protein comprises plant-derived cystatin DNA or protein respectively, and said at least one other part comprises animal-derived cystatin DNA or protein respectively.

Ideally said animal-derived DNA or protein corresponds to DNA or protein from the active site of animal-derived cystatin; and preferably said plant-derived cystatin DNA or protein corresponds to DNA or protein from a structural site or structural sites or said plant-derived cystatins.

- 5 Alternatively, said DNA sequence or protein comprises different sorts or types of plant-derived cystatins.

Alternatively again, said DNA sequence or protein comprises different sorts or types of animal-derived cystatin.

- 10 According to a yet further aspect of the invention there is provided protein and/or DNA sequence structure relating to a novel proteinase inhibitor comprising both the aforementioned hybrid proteinase inhibitor and also the aforementioned site-directed modification.

- 15 All of the proteinase inhibitors of the invention have application for countering the effects of proteinases and for use in methods relating to such effects.

- 20 Thus generally speaking the invention relates to the re-design of proteins which exhibit improved functional activities. Site-directed modifications or regions of amino acid sequence are replaced with either a corresponding region of a protein (from any organism) which exhibits the desired characteristics, or with designed synthetic sequences. The amino acid framework of the original protein is ideally maintained in the final hybrid molecule.

The invention will now be described by way of example only with reference to the following figures wherein:

Figure 1 shows the alignment sequence structure of a number of cystatins.

5 Figure 2 shows the DNA sequence structure of the novel protein of the invention.

Figure 3 shows the DNA sequence structure of the rice cysteine proteinase inhibitor Oryzacystatin Oc-I.

10 Figure 4 shows the effect of cystatin expression on growth of *G.pallida* females parasitising *A.rhizogenes*-transformed tomato roots. Body size of the nematode is given as the area of its outline in sq μm ; **a** controls, **b** and **c**, Oc-I and Oc-IdeltaD86 expression respectively.

Figure 5 shows the suppression of growth of fungi from spores over 6 days on agar after addition of a total of 45 $\mu\text{gPI(s)}$ to the central well.

15 Figure 6 shows the relative percentage inhibition of various hybrid proteinase inhibitors when exposed to their corresponding proteinases.

Table 1 shows the dissociation constant K_i of a variety of cystatins either in their native state or when subjected to specific modification.

Table 2 shows the sequence of 23 oligonucleotide primers (P1-23) used in PCR reactions and 2 linkers (L1-2) used in cloning.

Table 2a shows the sequences of primers (P24-39) used in PCR reactions to manufacture hybrid molecules.

Table 3 shows the nature of hybrid molecules manufactured. The bars indicate the length of Oc-I protein, areas shaded black represent the regions replaced by CEWC amino acid sequence.

Materials and Methods

Strains and vectors

DNA preparation and manipulation

Plasmid DNA was purified from *E-coli* cultures by the alkaline lysis method (2). Restriction digests and ligation reactions were carried out using the recommendations of the manufacturer. DNA fragments were recovered from agarose gels using an electroelution chamber (IBI) following the manufacturer's protocol. Oligonucleotides were synthesised on an Applied Biosystems 381A instrument and further purification was only performed for oligonucleotides used in "Altered Sites II" site directed mutagenesis protocols by using a reverse phase COP chromatography cartridge (Cruachem, Glasgow, UK). DNA sequencing of double stranded plasmid DNA was performed using Sequenase version 2.0 (Amersham) according to the manufacturer's instructions.

Cloning of cystatins and *C.elegans* proteinase inhibitor

Oc-I was amplified from genomic DNA of *Oryza sativa* L. *japonica* with

primers P1 and P2 (see Table 2) designed from published sequence data (3) and with the addition of restriction enzyme sites to assist cloning. The intron was removed by the PCR technique of gene SOEing (4a & 4b) where primer pairs P1/P3 and P2/P4 were used to amplify the two exons. These products were then SOEn together by amplifying with primers P1 and P4 and the product cloned into *Sma I/Eco R1* digested pBluescript. The sequence of the cloned coding region was verified by comparing with the published data for *Oc-I* (3). Amplification and intron removal of the *C.elegans* cysteine protease gene, *gcp-I*, were performed in a similar manner using primers P5-8 (Table 2) designed from sequence information (5). The final PCR product was cloned into pBluescript and checked by sequence analysis.

DNA sequence information for cowpea cysteine protease inhibitor, CCPI (6) was used to design oligonucleotide primers, P9 and P10 (Table 2). These primers together with a cDNA clone carrying the CCPI gene (kindly provided by Prof. P. Shewry) were used to PCR amplify a product that was cloned directly into the expression vector pQE30 (Qiagen, California, USA) utilising the *Bam HI* and *Hind III* sites incorporated into the PCR primers. Genes were cloned into the Type IV pQE expression vectors (Qiagen, California, USA) (*Bam HI/Hind III*) and proteins were expressed in the *E-coli* strain M15[pREP4].

Mutagenesis

a) N-terminal deletions

To generate the large 72bp deletion at the 5'-end of *Oc-I*, designated *pdelta24Oc-I*, pQE30/*Oc-I* was digested with *Sma I* and *Hinc II*, the large

fragment purified from an agarose gel and relegated. To create the 63bp deletion (termed pdelta21Oc-I), pQE30/Oc-I was restricted with Bam HI and Hinc II and gel purified. The 9bp region immediately 5' to the Hinc II site together with the sequence encoding the enterokinase recognition site was reintroduced by ligating the annealed oligonucleotide linkers L1 and L2 to the purified fragment.

b) C-terminal deletions

Exonuclease III/mung bean nuclease deletions were carried out (2) to generate deletions to 24, 27, 30 and 33bp at the 3'-end of the gene.

c) Point mutations

The "Unique Site Elimination" (USE) strategy (Pharmacia, Upsalla Sweden) was used to generate constructs expressing single codon alternations using primers P11-P20 (Table 2) which resulted in variant forms of Oc-I having the following amino acid alterations. i) insertion of Leu between 81 and 82. ii) deletion of E13; D86; A74; M85; iii) substitution of (from, No, to) D86N; E89L; Q91L; P83A; W84A. "Altered Sites II" system (Promega, Madison, USA) which involved subcloning Oc-I into the vector pALT-Ex2, (Promega, Madison, USA) was used to generate mutants in which the codons for P83, W84 and D86 were changed to the Amber stop codon (TAG). The oligonucleotides (P21-P23) used to achieve this as shown in Table 2 where the amber stop codons are shown in bold and the point mutation to remove a Sac I site (GAGCTC) is in lower case (this change does not alter the amino acid sequence). The absence of this Sac I site was used as a diagnostic test for mutants. The "Interchange" method (Promega, Madison, USA) was to

used to generate amino acid changes, to Cys, Glu, Phe, Gly, His, Pro, Arg, Lys, Gln, Ser and Tyr, at the Amber stop codon by introducing the mutant clones into twelve specific amber suppressing strains.

Expression of Oc-I and gcp-1 in *E coli*

- 5 Oc-I expressed from pQE30 ("QIAexpression" system) contained six N-terminal histidine residues, encoded by the vector to allow one-step Nickel chelate affinity. Oc-I protein was purified from 11 cultures of *E coli* M15 [pREP4] harbouring the pQE30 derived expression plasmid. 20ml of an overnight culture was inoculated into 1 litre of LB-media and grown at 37°C
- 10 to A₆₀₀ 0.7-0.9. IPTG was added to a final concentration of 2mM and growth was allowed to continue for a further 2 h. The cells were harvested by centrifugation at 10000g for 10 min, resuspended in 12ml of sonication buffer (50mM Na₂HPO₄, 300mM NaCl) and stored at -20°C overnight. The sample
- 15 was thawed, aliquoted to three 15ml tubes and sonicated on ice in short pulses (3x30 sec). Cell debris was pelleted by centrifugation (10000g) and approximately 0.5-0.75ml of Ni-NTA resin slurry (Qiagen, California, USA) was added to each tube and mixed gently on ice for 1h. The resin was collected (1000g for 1 min) and washed five times with 5ml of wash buffer (50mM Na₂HPO₄ pH 6.0, 500mM NaCl, 40mM imidazole at 4°C for 0.5h).
- 20 Protein was eluted with 1ml of elution buffer (50mM Na₂HPO₄, 300mM NaCl, 100mM EDTA) and the resin was repelleted at 1000g for 1 min and the elution repeated a further two times.

The *C.elegans* proteinase glp-1 was expressed in an identical manner.

Delta2IOc-I contained an enterokinase recognition sequence (Asp-Asp-Asp-

Asp-Lys) between the N-terminal six histidines (6x His-tail) and the N-terminal residue of the truncated Oc-I protein. Enterokinase (Boeringer) was used to cleave the 6x His-tail from Delta21Oc-I, which was purified from the 6x His-tail by nickel affinity chromatography. "Centricon 10s" (Amicon) were used according to instructions provided with the product to separate Oc-I from contaminating enterokinase.

Determination of Ki's

To determine the Ki of cystatins biochemical assays were performed according to the procedure of Barrett (7) and Ki values were calculated as described by Abe et al. (3)

SDS PAGE and western blot analysis

All purified proteins were analysed by SDS-PAGE (8). Western blots were performed according to the protocol for "mini protein II" (Biorad, Hertfordshire, UK) using PVDF membrane (Millipore, Massachusetts, USA).

Antibody production

Polyclonal antibodies against Oc-I were raised in male Wistar rats (6 weeks old). Three interperitoneal injections of 100 ug Oc-I in a final volume of 300ml were given at four week intervals. The first injection was an emulsion of protein and complete Freund's adjuvant in a 1:1 (v/v) ratio and the second and third injection were similar but used incomplete Freund's adjuvant. Ten days after the final injection, blood was collected and allowed to coagulate at 4°C before centrifugation at 5000g for 10 min. The resultant serum was

collected and stored in 50% (v/v) glycerol at -70°C. The serum gave optimal results in ELISA at a dilution of 1 in 10000 and recognised both native and denatured Oc-I protein.

ELISAs

- 5 ELISAs were performed to determine the level of expression of cystatins in transgenic roots. Root segments of about 2mm were ground in liquid nitrogen, transferred to a 15ml Falcon tube prior to the addition of 1ml of 0.5 x PBS was added and shaking at 4°C for 15 min to dissolve the soluble protein fraction. Protein was acetone precipitated and the precipitant was
10 resuspended in coating buffer (15mM Na₂HCO₃, 34mM NaHCO₃, pH 9.6). Protein concentration was determined by a standard assay (14). Wells of a Maxisorb microtitre plate were coated with 100mg protein for 48 h at 4°C. Plates were blocked with anti-Oc-I antibody (1 in 10,000 dilution). Activity was detected by adding substrate and the absorbance of the samples was
15 measured at 405nm when coloration developed.

Different amounts of Oc-I were added to aliquots of 100mg of total protein extracted from untransformed roots and used concurrently in ELISA assays with unknown samples to provide internal standards over the range of 0-2% Oc-I in total soluble protein.

20 Culture of *C.elegans*

Caenorhabditis elegans was cultured on NGM agar carrying a lawn of *E. coli* OP50 cells as described by Wood (9). Populations were maintained for 5 days before an agar plug was inserted into fresh media. When required,

cystatins were added to the media at a final concentration of 2.5mg l^{-1} just prior to polymerisation. Single nematodes were transferred from non-supplemented solid agar plates to plates containing Oc-I, DeltaD86 Oc-I or BSA. Where necessary ten replicates were carried out for each treatment.

5 Transgenic tomato root culture

Oc-I derivative genes were cloned into the vector pBIN19 and then introduced into *Agrobacterium rhizogenes* strain LBA9402 by electrotransformation for use in transformation of *Lycopersicon esculentum* cv Ailsa Craig by a standard protocol (15). Subsequently roots were grown on 0.5x Murashige and Skoog basal salts mixture supplemented with Gamborgs B5 vitamins and 3% sucrose (w/v) and 0.2% phytigel (w/v) plus 100mg l^{-1} kanamycin, solid medium, during initial selection. Western blots were used to confirm the presence of Oc-I or mutant forms in putatively transformed roots.

15 Challenge of roots by *Globodera pallida*

The J2 were obtained from cysts of *G.pallida* and sterilised extensively before use. The cysts were soaked in running tap water for 2-3 days followed by an overnight soak in 0.1% (v/v) malachite green at room temperature. Cysts were then rinsed for 8h in running tap water prior to soaking overnight at 4°C in an antibiotic cocktail (8mg ml^{-1} streptomycin sulphate, 6mg ml^{-1} penicillin G, 6.13mg ml^{-1} polymycin B, 5mg ml^{-1} tetracycline and 1mg ml^{-1} amphotericin B). The cysts were then washed in filter-sterilised tap water and set to hatch in filter-sterilised potato root diffusate. The overnight hatch of J2s was counted and sterilised sequentially

for 10 min with the following antibiotics; 0.1% streptomycin sulphate, 0.1% penicillin G, 0.1% amphotericin B and 0.1% cetyltrimethylammoniumbromide (Cetavlon). The nematodes were pelleted between treatments by brief microcentrifugation. They were washed extensively in filter sterilised tap water and used immediately. Roots of transformed lines were cultured for 4 weeks before 2cm lengths were transferred to fresh media. After a further 3-4 days, 5ml aliquots containing 35 J2s were pipetted onto each actively growing root approximately 1cm from its tip. A 1cm² piece of sterile GFA filter paper was placed over the area to aid infection and was removed 24 h later.

At harvest infected roots were removed from petri dishes, rinsed in water and placed in 1% (w/v) sodium hypochlorite for 2 min. For early time points, roots were plunged into boiling 0.1% aqueous acid fuchsin for 1 min, rinsed in water and then cleared in acidified glycerol at 60°C overnight to facilitate visualisation of nematodes. At the later time points, nematodes could be visualised without staining and were dissected from the roots. Nematodes were examined under a microscope (DBRM, Leica) at 50-200x magnification and the cross-sectional area was measured using an image analyser (Quantimet 5000C; Leica) attached to the microscope.

20 Demonstration of antifungal activity

We have shown that the PIs recovered after expression in pQE30 (see earlier) have anti-fungal activity. 45µg of the recovered PI were added at 1µg/µl to a central well within agar plates which contained spores of *B.cinerea* (2.2 x 10⁴/plate). The spores do not germinate and the fungus failed to grow where CPTI or Oc-I has diffused into the agar from the central well. The

potent effect persisted for many weeks and was enhanced by combining a serine and cysteine PI. Of particular relevance is that Oc-IdeltaD86 was more efficacious than the native form of Oc-I(Figure 3). We have also established that PIs have effects on other micro-organisms including

5 *Aspergillus fumigatus* (a fungal pathogen of mammals; Figure 5) and *Erwinia carotovora* (a bacterial pathogen of plants). This demonstrates two of the central points underpinning this application viz. (i)the approach has a broad potential against very different fungi (ii) protein engineering can enhance the efficacy of PIs against fungi.

10 **Formation of Hybrid Genes**

Chicken egg white cystain (CEWC) is a more potent inhibitor than either Oc-I or Oc-I Δ D86. We have replaced fragments of Oc-I with the corresponding sequences of CEWC in order to create a gene of essentially plant origin with the more potent inhibitory properties.

15 **Materials and Methods**

Replacement of the N-terminus of *oc-I* with the corresponding region of *cewc*.

Two oligonucleotide primers (P24 and P25) were synthesised which were overlapping at their 3' ends. These were annealed and filled-in with DNA

20 polymerase I (Klenow fragment) to generate a double-stranded full-length sequence encoding the N-terminus of the mature form of CEWC, **S E D R S R L L G A P V P V D** (residues 1-15, CEWC numbering). Primers P26 and P27 were used to amplify *oc-I* lacking the first 51 bp of coding sequence. The *oc-I* and *cewc* sequences were then joined by a PCR reaction known as

SOEing (4a & 4b) to generate hybrid gene termed *oc-nterm 1-15*.

Replacement of the central QVVAG and surrounding region of *oc-I* with the corresponding region of *cewc*.

5 A second hybrid molecule was constructed in which the central loop of the tripartite wedge, which comprises the active site of Oc-I, was replaced with the corresponding portion of CEWC. Four oligonucleotides (P28, P29, P30 and P31) were synthesised which when together encoded the CEWC sequence Y S S R V V R V I S A K R Q L V S G I K Y I L Q (residues 40-63). Primer pairs P28 / P29 and P30 / P31 were annealed and treated
10 with DNA polymerase I (Klenow fragment) to generate two double-stranded fragments which were subsequently SOEn together. Fragments of *oc-I* encoding both the N- and C-terminal regions were amplified using primers P32 / P33 and P27 / P34 respectively. The synthetic *cewc* sequence (P28-31) was SOEn to the N-terminal fragment of *oc-I* which was in turn SOE-n to the
15 C-terminal fragment of *oc-I* generating the hybrid gene *glvsg40-63*.

Replacement of the C-terminus of *oc-I* with the corresponding region of *cewc*.

The region of *cewc* encoding the C-terminal 20 amino acids, F V V Y S I P W L N Q I K L L E S K C Q (residues 97-116) was generated, using
20 primers P35 and P36 in an identical manner to that encoding the N-terminus described above. Primers P32 and P37 were used to amplify *oc-I* lacking the terminal 51 bp of coding sequence. The *oc-I* and *cewc* sequences were SOEn together to generate the hybrid termed *oc-cterm97-116*.

Generating hybrids with shorter cewc sequences

To determine whether shorter *cewc* regions could confer greater inhibitory potency than native Oc-I in a hybrid cystatin further hybrid molecules containing smaller regions of CEWC were generated. Such hybrid proteins would retain more of the amino acid sequence of the original plant molecule. Two primers P38 and P39, where used in USE mutagenic reactions, this generated two hybrid genes terms *oc-qlvsg52-60* and *oc-pw101-107* which encoded the contiguous *cewc* residues **R Q L V S G I K Y** (residues 52-60 critical *cewc* active site [12]) and **S I P W L N Q** (residues 101-107, important region of C-terminus [16]) respectively.

Generating a matrix of hybrid molecules.

Hybrid molecules in which multiple sections of *oc-I* have been replaced by the corresponding *cewc* sequences were generated by utilising conveniently situated restriction enzyme sites in *oc-I*. Sequences encoding the N-terminus of either the native *oc-I* or the N-terminal hybrid gene were removed by *Hinc* II restriction digest. Sequences encoding the C-terminus of either native *oc-I* of the C-terminal hybrid gene were removed by *Foc* I restriction digest. By ligating a fragment from one hybrid gene to that of another, further hybrid molecules were generated in which two or three of the original *oc-I* fragments were replaced by those of *cewc*. A total of 15 hybrid genes were constructed (Table 3).

RESULTS

Modelling

Protein sequence alignments were generated using the program SOMAP to align protein sequence selected from the OWL database. An initial alignment of cysteine proteinase sequences served to demonstrate the high degree of conservation throughout the cysteine proteinase family and also confirmed that using papain as our initial target was not unreasonable. A second aligned twenty five cysteine proteinase inhibitors (Figure 1) of available sequences was generated and served to highlight previously identified conserved amino acids and provided a basis for comparing known K_i values of cysteine protease inhibitors with sequence features, information which was used in the design of mutagenesis strategies.

For structural modelling the co-ordinates of hen egg white cystatin (10) and human stefin B/papain complex (11) were kindly provided by Prof. Bode. These were used to build a three dimensional model of OcI which was then energy minimised using the program Xplor to ensure that our model had reasonable stereochemistry.

Cloning expression and purification of *C.elegans* cysteine protease

In order to allow K_i values to be determined against both papain and a nematode protease the *C.elegans* cysteine proteinase was expressed and purified from *E coli* gcp-1 preparations and analysed by SDS PAGE to determine purity.

Expression and Mutagenesis of cystatins

Cystatins and Oc-I mutational variant proteins expressed and purified from *E coli* were analysed by SDS PAGE to determine the level of purity.

The alignment of the cysteine proteinase inhibitors (Figure 1) shows that Oryzacystatins have no leader sequence (unlike the maize homologues) and are therefore likely to be produced intracellularly. For the three wild type inhibitors, Cowpea protease inhibitor (CCPI), maize cystatin II and Oc-I
5 determination of K_i demonstrated that they have similar inhibitory activities. At the onset of the work CCPI was not characterised. For these reasons Oc-I was selected for mutational analysis.

Previously published reports suggested an N-terminally truncated form of Oc-I was marginally more efficacious than the native protein however, although
10 these variant Oc-I proteins lacked 21 and 24 amino acids of Oc-I they retain N-terminal sequences encoded by vector sequences which might therefore have contributed to interactions with the proteinase. To examine this question proteins were expressed with N-terminal 24 and 21 amino acid deletions and C-terminal 8, 9, 10, 11 and 12 amino acid deletions. The K_i
15 of these variant protein forms were determined using either papain or *C.elegans* protease, gcp-1 (Table 1). None of the truncated proteins were found to have a lower K_i than wild type Oc-I and both 21 and 24 amino acid deletions were inactive, suggesting that the results of other workers were due to the additional vector residues contributing to activity.

20 Protein sequence alignments and the model of Oc-I together with published K_i values for cystatins were used to identify mutations that might improve the inhibitory capability of Oc-I. The amino acid E13 and D86 were deleted independently. The deletion of residue E13 had no effect on the K_i Oc-I against either papain or gcp-1. Deletion of residue Delta86 lowered the K_i
25 of Oc-I approximately 13-fold from 7nM to 0.5 nM with papain and 8 nM to 0.6 nM with the *C.elegans* protease, gcp-1 (Table 1). The region of the

inhibitor around D86 was targeted for further mutagenesis. Table 1 shows Ki values for all the further mutations assayed against the *C.elegans* cysteine protease. It is apparent from these figures that all of the substitutional mutations led to an increased Ki suggesting a decreased efficacy. The only mutation which showed a similar or marginally decreased Ki value to that of wild type Oc-I was the deletion of residue M85 (from 8 to 7.1 nM with gcp-1).

In vivo effect of cystatins against *C.elegans*

Feeding trials were set up using *C.elegans* to examine the effect of protease inhibitors on nematode growth. As soon as hermaphrodites became apparent on normal agar they were transferred to individual plates containing either Oc-I, Oc-IdeltaD86, CCPI or BSA and egg laying was observed. Irrespective of the culture media the hermaphrodites laid a mean number of approximately 300 eggs. Half of these eggs were removed to normal plates containing no added inhibitor. The eggs were allowed to hatch and the development of the *C.elegans* larvae was monitored. Under all conditions greater than 95% of the eggs hatched and development was completed for 94%, 92.5%, 97% and 96% of those hatched from eggs recovered from Oc-I, Oc-IdeltaD86, CCPI and BSA supplemented media respectively.

In a second experiment larvae hatching under normal conditions were removed to media supplemented with a protein as above. 50 larvae were transferred at 6 h, 12 h, 24 h and 30 h corresponding to the developmental times when the four larval stages L1, L2, L3 and L4 predominate. No larvae developed to an adult when transferred to media supplemented with Oc-I, Oc-IdeltaD86 or CCPI at 6, 12 or 24 h after hatching. The larvae which failed

to develop on cystatin supplemented media became moribund and failed to recover on transfer to fresh non-supplemented plates. These larvae also failed to move or respond to repeated tactile stimuli and eventually died. However 76% of larvae transferred at 30 h after hatching developed to reach the adult male or hermaphrodite stages. All juveniles hatched from eggs laid on media containing BSA and transferred to normal media developed into adult nematodes.

In vivo effect of cystatin against *Globodera pallida*

Preliminary assays with Oc-I and Oc-IdeltaD86 demonstrated that anti-Oc-I polyclonal antibodies both recognised both proteins equally well. ELISA established that the highest level of expression in an Oc-I expressing transformed tomato hair root line was $0.54 \pm 0.02\%$ of the total soluble protein. Similar assays identified a Oc-IdeltaD86 line with a similar level of expression of $0.51 \pm 0.01\%$ of the total soluble protein fraction which was selected for comparative studies. The growth of nematodes on the two transgenic cystatin lines and an untransformed control was measured for individuals recovered from several roots at approximately weekly intervals for 6 weeks. Image analysis provided values for the area of the nematode outline. Means for these values are given against time for three root lines in Figure 4. Statistical analysis was carried out using oneway ANOVA with an *a priori* contrast (12) to compare the two cystatin lines against the control for each day of measurement. This analysis establishes a significantly lower outline area ($P < 0.05$) at 1, 2, 4, 5 and 6 weeks. Furthermore no significant increase in size occurred between 4 and 6 weeks for animals on Oc-IdeltaD86 line ($P < 0.05$; SNK) in contrast to the other two lines.

Comparative assays as described by Urwin et al (16) in which inhibition by CEWC was determined arbitrarily as 100%, have been carried out the first seven hybrid molecules listed in Table 3. Of those seven only one, OC-
NTERM1-15QVLSG40-63CTERM97-116, which contains 57 CEWC residues
5 displayed inhibition of c.a. 90%. This was greater than native Oc-I (c.a. 60%) and Oc-I Δ D86 (c.a. 88%). The level of inhibition observed for the remaining six hybrid molecules was reduced (Fig. 6).

Discussion

It can be seen from the data shown in Table 1 that removal of the aspartic
10 acid at amino acid position 86 improved the Ki value some 13-14 fold whilst deleting methionine at neighbouring position 85 had only a marginal effect on papain inhibition. Additionally, substitution of aspartic acid at position 86 by 12 other amino acids had a detrimental effect on Ki. Therefore, removal of one amino acid, thus shortening the protein backbone, seems to
15 be a significant factor in improving Ki. Moreover, the removal of an amino acid at position 86 seems to be important. We consider that the loop containing this residue is part of the inhibitory site of the molecule with deletion of amino acid aspartic acid 86 resulting in a more similar structure to that of other cystatins perhaps improving the interaction of the conserved
20 above referred to PW site at amino acid positions 83 and 84 with the proteinase.

In Table 1 it can be seen that the efficacy of the native and modified proteinase inhibitors was determined having regard to papain and also gcp-1 derived from the bacteria-feeding nematode *C. elegans*.

Moreover, other information presented herein shows that the modified protein is effective at inhibiting proteinases and so functionally active.

5 In addition, our data relating to hybrid molecules shows that it is possible to engineer proteins and in particular to modify plant proteins to include at least a part of an animal protein so that the functional effectiveness of a proteinase inhibitor is improved, that is to say the functional effectiveness of a plant protein approaches that of an animal protein.

10 Our data indicates that previous reports of inadequate control of insects at achievable levels of expression of native proteinase inhibitors may be overcome by using protein engineering as demonstrated in the present application. We have shown that protein engineering can lower and so improve K_i values and so reduce the minimum effective protein level that must be expressed in plants for effective plant protection.

REFERENCES

- 1) Peng, JH & Black LL (1976) *Phytopathology*. 66:958-963.
- 2) Maniatis T., Fritsch EF & Sambrook J (eds)(1982). Molecular cloning a laboratory manual. *Cold Spring Harbor Laboratory*. pp545
- 5 3) Abe K, Emori Y, Kondo H, Suzuki K & Arai S. (1987). Molecular cloning of a cysteine proteinase inhibitor of rice (Orozacystatin) Homology with animal cystatins and transient expression of the ripening process of rice seeds. *The Journal of Biological Chemistry*. 262: 16793-16797.
- 4a) Ho SN, Hunt HD, Horton RM, Pullen JK and Pease LR (1989).
10 *Gene* 77: 51.
- 4b) Horton RM, Hunt HD, Ho SN, Pullen JK and Pease LR (1989).
Gene 77: 61.
- 5) Ray C and McKerrow JH (1992). Gut-specific and developmental expression of a *Caenorhabditis elegans* cysteine protease gene. *Molecular and Biochemical Parasitology*. 51: 239-250.
15
- 6) Fernandes KVS, Sabelli PA, Barratt DHP, Richardson M, Xavier-Filho J and Shewry PR (1993). The resistance of cowpea seeds to bruchid beetles is not related to levels of cysteine proteinase inhibitors. *Plant Molecular Biology* 23: 215-219.
- 20 7) Barrett AJ (1972). A new assay for Cathepsin B1 and other thiol

proteinases. *Analytical Biochemistry* 47: 280-293.

- 8) **Hames BD and Rickwood D**(eds)(1981). Gel electrophoresis of proteins a practical approach. *IRL press limited* pp290.
- 9) **Wood B** (ed)(1988). The nematode *C.elegans*. *Cold Spring Harbor Laboratory press*. pp606.
- 10) **Bode W, Engh R, Musil D, Thiele U, Huber R, Karshikov A, Brzin J, Kos J and Turk V** (1988). The 2.0 Å X-ray crystal structure of chicken egg white cystatin and possible mode of interaction with cysteine proteinases. *The EMBO Journal* 7: 2593-2599.
- 10 11) **Stubbs M, Laber B, Bode W, Huber R, Jerala R, Lenarcic B** (1990). The refined 2.4 Å X-ray crystal structure of combinant human stefin B in complex with the cysteine proteinase papain: a novel type of proteinase inhibitor interaction. *The EMBO Journal* 9: 1939-1947.
- 15 12) **Arai S, Watanabe H, Kondo, Emori Y and Abe K** (1991). Papain-inhibitory activity of oryzacystatin, a rice seed cysteine protease inhibitor, depends on the central Gin-Val-Val-Ala-Gly region conserved among cystatin superfamily members. *J Biochem.* 109:294-298.
- 20 13) **Sijmons PC, Atkinson HJ and Wyss U** (1994). Parasitic Strategies of Root Nematodes and Associated Host Cell Responses. *Annual Review of Phytopathology* 32:235-259.
- 14) **Bradford M**, (1976). A rapid and sensitive method for the quantitation

of microgramme quantities of protein utilising the principle of protein dye binding. *Analytical Biochemistry* 72:248-254.

- 5 15) **Tefer D** (1984). Transformation of several species of higher plant by *Agrobacterium rhizogenes*. Sexual transmittion of the transformed genotype and phenotype. *Cell* 37:959-967.

- 16) **Urwin PE, Atkinson, HJ, Waller D and McPherson MJ** (1995). Engineered Oryzacystatin-I expressed in transgenic hairy roots confers resistance to *Globodera pallida*. *The Plant Journal* 8: 121-131.

CLAIMS

1. A proteinase inhibitor modified or manufactured so that it is more effective at inhibiting a proteinase with which it interacts than its corresponding naturally occurring counterpart.
- 5 2. A proteinase inhibitor according to claim 1 wherein the inhibitor binds more strongly to the said proteinase.
3. A proteinase inhibitor according to claims 1 or 2 wherein the inhibitor has a K_i at least ten times lower than its natural counterpart.
- 10 4. A proteinase inhibitor according to any preceding claim including at least one site-directed amino acid deletion.
- 15 5. A proteinase inhibitor according to claim 4 wherein the deletion concerns deletion of aspartic acid at position 163 of an amino acid sequence structure which is aligned with the alignment amino acid sequence structure shown in Figure 1, or alternatively deletion of its functional counterpart in related proteinase inhibitors.
6. A proteinase inhibitor according to claim 5 wherein said inhibitor is a cystatin.
- 20 7. A proteinase inhibitor according to claim 5 or 6 wherein the protein is Oryzacystatin-I(Oc-I) and the deletion is deletion of the aspartic acid at position 86 of this protein.

8. A proteinase inhibitor according to claims 4 to 7 wherein said deletion is followed by a substitution at said position for an alternative amino acid.
9. A proteinase inhibitor according to claim 8 wherein said alternative amino acid has counter properties having regard to the functional properties of the eliminated aspartic acid.
10. Use of a proteinase inhibitor according to any preceding claim to counter the effects of a corresponding proteinase.
11. Use according to claim 10 wherein the inhibitor is used as a medicament.
- 10 12. Use according to claim 10 wherein the inhibitor is used as a pesticide.
13. A composition for use in countering the effects of a proteinase comprising at least a proteinase inhibitor according to claims 1 to 9.
14. A composition according to claim 13 which further includes a suitable carrier.
- 15 15. The DNA sequence structure corresponding to a proteinase inhibitor in accordance with any of claims 1 to 9.
16. A construct including the DNA sequence structure according to claim 15.
17. An organism transformed with the construct according to claim 16.

18. An organism according to claim 17 which is a plant.
19. A method of conferring resistance to proteolytic damage comprising modifying or transforming an organism so that it expresses an inhibitor according to any of claims 1 to 9.
- 5 20. A method according to claim 19 whereby said expression is selected so that expression can occur either temporarily or locally so that the inhibitor is either expressed at a given selected point in time or at given location with respect to the physiology and/or anatomy of the organism.
- 10 21. A method according to claims 19 or 20 wherein said organism is a plant.
22. A method according to claim 21 wherein said plant is a cereal crop.
- 15 23. A method of producing a proteinase inhibitor according to claims 1 to 9 wherein a host organism is transformed such that its genetic material includes DNA sequence structure relating to a proteinase inhibitor according to any of claims 1 to 9 and then said transformed organism is cultured and/or cultivated under conditions wherein said proteinase inhibitor is expressed with a view to harvesting same.
- 20 24. A method of controlling a pathogen, parasite or pest comprising exposing said pathogen, parasite or pest to a proteinase inhibitor according to claims 1 to 9.
25. A method for producing a proteinase inhibitor according to claims 1

to 9 which comprises the use of any one or more of the primers shown in Table 2, or primers of similar nature having additions, deletions or modifications thereto which still enables the primer to produce a modified proteinase inhibitor as herein described.

5 26. Primers according to claim 25.

27. A hybrid proteinase inhibitor comprising a first part corresponding to a first proteinase inhibitor and at least one other part corresponding to at least one other proteinase inhibitor.

10 28. A proteinase inhibitor according to claim 27 wherein at least one of said parts corresponds to a cystatin.

29. A proteinase inhibitor according to claims 27 or 28 wherein at least a second part corresponds to a cystatin.

30. A proteinase inhibitor according to claims 27 to 29 wherein at least one cystatin is of plant origin.

15 31. A proteinase inhibitor according to claims 27 to 30 wherein said first part corresponds to a plant cystatin and said at least one other part corresponds to an animal cystatin.

20 32. A proteinase inhibitor according to claims 30 or 31 wherein said plant cystatin part corresponds to the structural portion of said corresponding plant cystatin.

33. A proteinase inhibitor according to claims 31 or 32 wherein said animal cystatin corresponds to an active portion of the corresponding animal cystatin.
34. A proteinase inhibitor according to claims 27 to 33 wherein said
5 inhibitor comprises a multitude of parts, each part corresponding to a proteinase inhibitor and the nature of each part selected so as to optimise the functional characteristics of the hybrid molecule.
35. A proteinase inhibitor according to claim 34 wherein a first part
10 corresponds to least a part of a proteinase inhibitor according to claims 1 to 9 and at least a second part corresponds to at least a part of proteinase inhibitor according to claims 27 to 34.
36. DNA sequence structure corresponding to the proteinase inhibitor according to claims 27 to 35.
37. A construct including the DNA sequence structure according to claim
15 36.
38. A host cell transformed with either the DNA sequence structure according to claim 36 and/or the construct according to claim 37.
39. Use of a proteinase inhibitor according to claims 27 to 35 to counter the effects of a corresponding proteinase.
- 20 40. Use according to claim 39 wherein the inhibitor is used as a medicament.

41. Use according to claim 39 wherein the inhibitor is used as a pesticide.

42. A composition for use in countering the effects of a proteinase comprising at least a proteinase inhibitor according to claims 27 to 35.

5 43. A composition according to claim 42 which further includes a suitable carrier.

44. A method of conferring resistance to proteolytic damage comprising modifying or transforming an organism so that it expresses an inhibitor according to claims 27 to 35.

10 45. A method according to claim 44 whereby said expression is selected so that expression can occur either temporary or locally so that the inhibitor is either expressed at a given selected point in time or at a given location with respect to the physiology and/or anatomy of the organism.

46. A method according to claims 44 or 45 wherein said organism is a plant.

15 47. A method of producing a proteinase inhibitor according to claims 27 to 35 wherein a host organism is transformed such that its genic material includes DNA sequence structure according to claim 36 and then said transformed organism is cultured and/or cultivated under conditions wherein said proteinase inhibitor is expressed with a view to harvesting same.

20 48. A method of controlling a pathogen, parasite or pest comprising exposing said pathogen, parasite or pest to a proteinase inhibitor according

to claims 27 to 35.

49. A method of producing a proteinase inhibitor according to claims 27 to 35 which comprises the use of any one or more of the primers should in Table 2a, or primers of similar nature having additions, deletions or
5 modifications thereto which still enables the primer to produce a modified proteinase inhibitor as herein described.

50. Primers according to claim 49.

1/11

	1:.....11:.....21:.....31:.....41:.....51:.....61:.....71:.....	
CYTA_HUMANMIPGGLSAPATATITICIVON
CYTA_RATMIPGGLSAPATATITICIVON
CYTB_RATMIPGGLSAPATATITICIVON
CYTB_BOVINMIPGGLSAPATATITICIVON
CYT1_MOUSEMIPGGLSAPATATITICIVON
CYT2_MOUSEMIPGGLSAPATATITICIVON
CYT3_MOUSEMIPGGLSAPATATITICIVON
CYTB_HUMANMIPGGLSAPATATITICIVON
CYT1_ORYSAMIPGGLSAPATATITICIVON
CYT1_ORYSA-D86MIPGGLSAPATATITICIVON
CYT2_ORYSAMIPGGLSAPATATITICIVON
CYT_COWPMIPGGLSAPATATITICIVON
CYT1_MAIZEMIPGGLSAPATATITICIVON
CYT2_MAIZEMIPGGLSAPATATITICIVON
CYT_CHICKMIPGGLSAPATATITICIVON
CYTC_BOVINMIPGGLSAPATATITICIVON
CYTC_HUMANMIPGGLSAPATATITICIVON
CYTC_MOUSEMIPGGLSAPATATITICIVON
CYTC_RATMIPGGLSAPATATITICIVON
CYTD_HUMANMIPGGLSAPATATITICIVON
CYTN_HUMANMIPGGLSAPATATITICIVON
CYTS_HUMANMIPGGLSAPATATITICIVON
CYTS_RATMIPGGLSAPATATITICIVON
CYTT_HUMANMIPGGLSAPATATITICIVON
CYTX_ONCVMIPGGLSAPATATITICIVON
CYT_BITARMIPGGLSAPATATITICIVON
CYTL_DROMEMIPGGLSAPATATITICIVON
CYTA_SARPEMIPGGLSAPATATITICIVON
	76:.....86:.....96:.....106:.....116:.....126:.....136:.....146:.....	
CYTA_HUMANMIPGGLSAPATATITICIVON
CYTA_RATMIPGGLSAPATATITICIVON
CYTB_RATMIPGGLSAPATATITICIVON
CYTB_BOVINMIPGGLSAPATATITICIVON
CYT1_MOUSEMIPGGLSAPATATITICIVON
CYT2_MOUSEMIPGGLSAPATATITICIVON
CYT3_MOUSEMIPGGLSAPATATITICIVON
CYTB_HUMANMIPGGLSAPATATITICIVON
CYT1_ORYSAMIPGGLSAPATATITICIVON
CYT1_ORYSA-D86MIPGGLSAPATATITICIVON
CYT2_ORYSAMIPGGLSAPATATITICIVON
CYT_COWPMIPGGLSAPATATITICIVON
CYT1_MAIZEMIPGGLSAPATATITICIVON
CYT2_MAIZEMIPGGLSAPATATITICIVON
CYT_CHICKMIPGGLSAPATATITICIVON
CYTC_BOVINMIPGGLSAPATATITICIVON
CYTC_HUMANMIPGGLSAPATATITICIVON
CYTC_MOUSEMIPGGLSAPATATITICIVON
CYTC_RATMIPGGLSAPATATITICIVON
CYTD_HUMANMIPGGLSAPATATITICIVON
CYTN_HUMANMIPGGLSAPATATITICIVON
CYTS_HUMANMIPGGLSAPATATITICIVON
CYTS_RATMIPGGLSAPATATITICIVON
CYTT_HUMANMIPGGLSAPATATITICIVON
CYTX_ONCVMIPGGLSAPATATITICIVON
CYT_BITARMIPGGLSAPATATITICIVON
CYTL_DROMEMIPGGLSAPATATITICIVON
CYTA_SARPEMIPGGLSAPATATITICIVON

Figure 1

SUBSTITUTE SHEET (RULE 26)

2/11

```

151:.....161:.....171:.....181:.....191:.....201:.....211:.....221:
CYTA_HUMAN  MEL-EVLSLEGGNEHLVLYLQVVERNSDDELLAG
CYTA_RAT     LEM-EVLRLSGDDELLILQVVERNSDDELLAG
CYTB_RAT     CVHL-EVLSLEGGNEHLVLYLQVVERNSDDELLAG
CYTB_BOVIN  VHEI-EVLSLEGGNEHLVLYLQVVERNSDDELLAG
CYT1_MOUSE  LEM-EVLSLEGGNEHLVLYLQVVERNSDDELLAG
CYT2_MOUSE  LEM-EVLSLEGGNEHLVLYLQVVERNSDDELLAG
CYT3_MOUSE  LEM-EVLSLEGGNEHLVLYLQVVERNSDDELLAG
CYTB_HUMAN  MEL-EVLSLEGGNEHLVLYLQVVERNSDDELLAG
CYT1_ORYSA  ELDAEAVDEH-EVLSLEGGNEHLVLYLQVVERNSDDELLAG
CYT1_ORYSA-D86 ELDAEAVDEH-EVLSLEGGNEHLVLYLQVVERNSDDELLAG
CYT2_ORYSA  ELDAEAVDEH-EVLSLEGGNEHLVLYLQVVERNSDDELLAG
CYT_COWP    ELDAEAVDEH-EVLSLEGGNEHLVLYLQVVERNSDDELLAG
CYT1_MAIZE  ELDAEAVDEH-EVLSLEGGNEHLVLYLQVVERNSDDELLAG
CYT2_MAIZE  ELDAEAVDEH-EVLSLEGGNEHLVLYLQVVERNSDDELLAG
CYT_CHICK   TCHL-EVLSLEGGNEHLVLYLQVVERNSDDELLAG
CYTC_BOVIN  LCHL-EVLSLEGGNEHLVLYLQVVERNSDDELLAG
CYTC_HUMAN  LCHL-EVLSLEGGNEHLVLYLQVVERNSDDELLAG
CYTC_MOUSE  LCHL-EVLSLEGGNEHLVLYLQVVERNSDDELLAG
CYTC_RAT    LCHL-EVLSLEGGNEHLVLYLQVVERNSDDELLAG
CYTD_HUMAN  LCHL-EVLSLEGGNEHLVLYLQVVERNSDDELLAG
CYTN_HUMAN  LCHL-EVLSLEGGNEHLVLYLQVVERNSDDELLAG
CYTS_HUMAN  LCHL-EVLSLEGGNEHLVLYLQVVERNSDDELLAG
CYTS_RAT    LCHL-EVLSLEGGNEHLVLYLQVVERNSDDELLAG
CYTT_HUMAN  LCHL-EVLSLEGGNEHLVLYLQVVERNSDDELLAG
CYTX_ONCVC  VMEL-EVLSLEGGNEHLVLYLQVVERNSDDELLAG
CYT_BITAR   TCHL-EVLSLEGGNEHLVLYLQVVERNSDDELLAG
CYL_DROME   QCHV-EVLSLEGGNEHLVLYLQVVERNSDDELLAG
CYTA_SARPE  TCHL-EVLSLEGGNEHLVLYLQVVERNSDDELLAG

```

Figure 1 continued

3/11

Figure 2**The DNA coding sequence for Oryzacystatin-1AD86**

ATGTCGAGCG ACGGAGGGCC GGTGCTTGGC GGCCTCGAGC CGGTGGGGAA
CGAGAACGAC CTCCACCTCG TCGACCTCGC CCGCTTCGCC GTCACCGAGC
ACAACAAGAA GGCCAATTCT CTTCTAGAGT TCGAGAAGCT TGTGAGTGTG
AGGCAGCAAG TTGTCGCTGG CACTTTGTAC TATTCACAA TTGAGGTGAA
GGAAGGGGAT GCCAAGAAGC TCTATGAAGC TAAGGTCTGG GAGAAACCAT
GGATG TT CAAGGAGCTC CAGGAGTTCA AGCCTGTCGA TGCCAGTGCA
AATGCC

4/11

Figure 3.**We have underlined the coding sequence.**GGCCGAGGCG CATCGCGCAG GGGGAGAAGG GGAGGAGAAG ATGTCGAGCGACGGAGGGCC GGTGCTTGGC GGCCTCGAGC CGGTGGGGAA CGAGAACGACCTCCACCTCG TCGACCTCGC CCGCTTCGCC GTCACCGAGC ACAACAAGAAGGCCAATTCT CTTCTAGAGT TCGAGAAGCT TGTGAGTGTG AGGCAGCAAGTTGTCGCTGG CACTTTGTAC TATTTACAA TTGAGGTGAA GGAAGGGGATGCCAAGAAGC TCTATGAAGC TAAGGTCTGG GAGAAACCAT GGATG TTCAAGGAGCTC CAGGAGTTCA AGCCTGTCGA TGCCAGTGCA AATGCCTAAG

GCCCATCTCG ATCCTATGTG TATCAAGTTA TCTTGTTGAT GGGGAATAAT




ATGTTGTGGA TATAGCTATT GGACATGTGA AATTATCCACA TGATAATATG

GCTTGATAT AAGGATCTCA CACGATAATA TGGCTTGGAT ATATAGCTAT

AAAGATTTAC CTATGGCATA TTCAATGTGT ATTAGTACTA AGTAAGAATG

ATTGCAAGGT GTATTAATA CAAATATTGC AATAAAAGTC CCTGTTAC

5/11

Figure 4

6/11




Figure 5

SUBSTITUTE SHEET (RULE 26)

Cystatin	Mutagenised Amino acid(s)	7/11 Change	K _i (nM)	
			Papain	gcp-1
Maize cystatin-II	None		6.5 ±0.08	7.2 ±0.16
Cowpea cystatin	None		6.1 ±0.10	7.2 ±0.18
Oryzacystatin-I	None		7.0 ±0.13	8.0 ±0.14
Δ85Oc-I	Met85	Δ	-	7.1±0.17
Δ86Oc-I	Asp86	Δ	0.5±0.18	0.6±0.16
83Oc-I	Pro83	C,E,F,G,H,R,L,K,Q,S,Y,A	-	↑
84Oc-I	Trp84	C,E,F,G,H,R,L,K,Q,S,Y,P,A	-	↑
86Oc-I	Asp86	C,E,F,G,H,R,L,K,Q,S,Y,P,N	-	↑

Table 1


8/11

Primer	Sequence
P1	ACATGTCGAATTCTTAGGCATTTGCACTGGC
P2	GAGGAGCCCCGGGTCGAGCGACGGA
P3	CTCGAACTCTAGAAGAGAATTGGCCTTGTTGTG
P4	AATTCTCTTCTAGAGTTC
P5	CACGTGAATTCATGAAGTTCCTTATCCTTACCGCGCTCTGCGC
P6	CACGGCCTGCAGTTAGACCTTGGCCTTCCGGCGACAACCTGC
P7	GAACAGCGTAGGCAGAGACTCCGAAGTGCTTGTCCTTGGCGT
P8	GAGTCTCTGCCTACGCTGTTC
P9	ACTATGGATCCGCAGCACTCGGTGGCAATCG
P10	ATATTAAGCTTACACTATGCAGGTGCATTCCC
P11	CTTGGCGGCGTCCCGGTGGGGAAC
P12	AAACCATGGATGTTCAAGGAGCTC
P13	AAACCATGGGACTTCAAGCCT
P14	GAGAAACCAAACATGGACTTC
P15	GAGAAACCAGCGATGGACTTC
P16	TGGGAGAAAGCATGGATGGAC
P17	AAGGAGCTCCTGGAGTTCAAG
P18	GACTTCAAGATACTCCAGGAG
P19	TGGGAGAAACTGCCATGGATG
P20	AAGCTCTATGAAAAGGTCTGG
P21	GTCTGGGAGAAATAGTGGATGGACTTCAACGA ₂ CTCCAG
P22	GTCTGGGAGAAACCATAGATGGACTTCAACGA ₂ CTCCAG.
P23	GTCTGGGAGAAACCATGGATGTAGTTCAACGA ₂ CTCCAG.
L1	GATCCGATGACGATGACAAACACCTCGTC
L2	GACGAGGTGTTTGTGCATCGTCATC

Table 2

9/11

Figure 6



SUBSTITUTE SHEET (RULE 26)


10/11

Table 2 A

<u>Primer No.</u>	<u>Primer sequence (5' → 3')</u>
P24	AGCGAGGACCGCTCCCGGCTCCTGGGGGCTCCA
P25	GTCGTCGTTCTCATCTACAGGCACTGGAGCCCCCAG
P26	GAGAACGACCTCCACCTCGTC
P27	GGCATTGTGCACTGGCATCGAC
P28	AAGGCCAATTCTCTTTACTCCAGCCGGGTGGTGCGGGTCATC
P29	CACGAGCTGCCGCTTGGCGCTGATGACCCGCAC
P30	CGGCAGCTCGTGTCTGGAATCAAGTACATC
P31	ATCCCCTTCCTTCACCTGCAGGATGTACTTGATTCCAGA
P32	ATGTCGAGCGACGGAGGGCCGGTG
P33	AAGAGAATTGGCCTTCTTGTT
P34	GTGAAGGAAGGGGATGCCAAGAAG
P35	GCCAAGAAGCTCTATTTTGTAGTGTACAGTATTCCTTGGCTA
P36	CTGGCACTTGCTTTCCAGCAGTTTAATTTGGTTTAGCCAAGGAAT
P37	ATAGAGCTTCTTGGCATCCCCTTCCTT
P38	AAGGTCTGGTCGATACCATGGCTGAACCAAAGGAGCCT
P39	AGTGTGAGGCGGCAACTTGTCTCTGGCATTAAGTACTACTTCACA

Table 3

- 1) *oc-interm1-15*
- 2) *oc-qvls40-63*
- 3) *oc-cterm97-116*
- 4) *oc-interm1-15qvls40-63*
- 5) *oc-interm1-15cterm97-116*
- 6) *oc-qvls40-63cterm97-116*
- 7) *oc-interm1-15qvls40-63cterm97-116*
- 8) *oc-qlvsg52-60*
- 9) *oc-pw101-107*
- 10) *oc-qlvsg52-60pw101-107*
- 11) *oc-interm1-15qlvsg52-60*
- 12) *oc-interm1-15pw101-107*
- 13) *oc-qlvsg52-60cterm97-116*
- 14) *oc-qvls40-63pw101-107*
- 15) *oc-interm1-15qlvsg52-60cterm97-116*



— 10 amino acids

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/15, C07K 14/81, A61K 38/55, C12N 15/62, A01H 5/00, C12N 1/21, A01N 33/16		A3	(11) International Publication Number: WO 96/16173 (43) International Publication Date: 30 May 1996 (30.05.96)
(21) International Application Number: PCT/GB95/02711 (22) International Filing Date: 20 November 1995 (20.11.95) (30) Priority Data: 9423477.0 21 November 1994 (21.11.94) GB 9423450.7 21 November 1994 (21.11.94) GB (71) Applicant (for all designated States except US): THE UNIVERSITY OF LEEDS [GB/GB]; Leeds LS2 9JT (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): ATKINSON, Howard, John [GB/GB]; 43 Sutherland Avenue, Leeds LS8 1BY (GB). McPHERSON, Michael, John [GB/GB]; 45 Henley Avenue, Thornhill, Dewsbury WF12 0LN (GB). URWIN, Peter, Edward [GB/GB]; 86 Swinnow Close, Bramley, Leeds LS13 4NF (GB). (74) Agent: WILLIAM, Jones; The Crescent, 54 Blossom Street, York, North Yorkshire YO2 2AP (GB).		(81) Designated States: AL, AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, LS, MW, SD, SZ, UG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> (88) Date of publication of the international search report: 17 October 1996 (17.10.96)	
(54) Title: MODIFIED PROTEINASE INHIBITORS			
(57) Abstract The invention relates to proteinase inhibitors, in particular cystatins, which has been modified so as to enhance their effective or synthetically manufactured counterparts. The modification including either site-directed alterations in the structure of the protein and/or the production of hybrid molecules.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 95/02711

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/15 C07K14/81 A61K38/55 C12N15/62 A01H5/00
C12N1/21 A01N33/16

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO,A,88 09384 (NORDISK GENTOFTE) 1 December 1988 cited in the application	1-4, 8-11, 13-17, 23,25,50
Y	see the whole document	5-24, 27-49
X	WO,A,92 06111 (NOVONORDISK AS) 16 April 1992 see abstract	1,4,10, 11, 13-17,23
X	WO,A,93 04082 (BAXTER INT) 4 March 1993 see the whole document	1,2,4, 8-11, 13-17,23
	--- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

29 August 1996

Date of mailing of the international search report

02.09.96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Van der Schaal, C

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 95/02711

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	PROTEIN EXPRESSION PURIF 3 (1). 1992. 41-49. CODEN: PEXPEJ ISSN: 1046-5928, XP002004754 CHEN M-S ET AL: "RICE CYSTATIN BACTERIAL EXPRESSION PURIFICATION CYSTEINE PROTEINASE INHIBITORY ACTIVITY AND INSECT GROWTH SUPPRESSING ACTIVITY OF A TRUNCATED FORM OF THE PROTEIN."	26,50
Y	see the whole document	5-25, 27-49

Y	EMBO JOURNAL, vol. 9, no. 6, 1990, pages 1939-1947, XP002004755 M. STUBBS ET AL: "The refined 2.4 A X-ray crystal structure of recombinant stefin B in complex with the cysteine proteinase papain" see the whole document	5-25

X	MOLECULAR AND BIOCHEMICAL PARASITOLOGY, vol. 51, 1992, pages 239-250, XP002004884 C. RAY AND J. MCKERROW: "Gut-specific and developmental expression of a Caenorhabditis elegans cysteine protease gene" cited in the application see figure 1	26

X	PLANT MOLECULAR BIOLOGY, vol. 23, 1993, pages 215-219, XP002004756 K. FERNANDES ET AL: "The resistance of cowpea seeds to bruchid beetles is not related to levels of cysteine protease inhibitors" cited in the application see reference to accession number Z21954 of the EMBL, GenBank and DDBJ Nucleotide Seq. Database page 215, last lines	26

X	US,A,5 124 443 (COLELLA RITA ET AL) 23 June 1992	50
Y	see the whole document	5,6, 8-25, 27-49

	-/--	

INTERNATIONAL SEARCH REPORT

Patent Application No

PCT/GB 95/02711

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	PLANT MOL BIOL 21 (4). 1993. 655-663. CODEN: PMBIDB ISSN: 0167-4412, XP002004757 MASOUD S A ET AL: "EXPRESSION OF A CYSTEINE PROTEINASE INHIBITOR ORYZACYSTATIN I IN TRANSGENIC TOBACCO PLANTS." see the whole document	17-22, 44-46
X	EP,A,0 511 393 (NIPPON MINING CO) 4 November 1992	27
Y	see the whole document	27-48
P,X	WO,A,95 23229 (UNIV LEEDS ;ATKINSON HOWARD JOHN (GB); KORITSAS VAS MICHAEL (GB);) 31 August 1995	26
Y	see the whole document especially SEQ ID NO 1-4	5-25, 44-46
P,X	PLANT JOURNAL 8 (1). 1995. 121-131. ISSN: 0960-7412, XP002004758 URWIN P E ET AL: "Engineered oryzacystatin -I expressed in transgenic hairy roots confers resistance to Globodera pallida." see the whole document	1-26

INTERNATIONAL SEARCH REPORT

national application No.

PCT/GB95/02711

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
- claims 10-12, 19, 20, 24, 39-41, 44, 45 and 48 - See continuation-sheet
PCT/ISA/210 *)
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such
an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6 4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. claims 1-26, 35 completely; 36-49 partially
 2. claims 27-34, 50 completely; 36-49 partially
- see continuation-sheet PCT/ISA/210 -

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/GB95/02711

FURTHER INFORMATION CONTINUED FROM PCT/ISA/210

1. Modified proteinase inhibitor with at least one site directed amino acid deletion, its use, hybrids containing it and DNA coding for these inhibitors
 2. Hybrid proteinase inhibitor comprising a first part corresponding to a first proteinase inhibitor and at least one other part corresponding to at least one other proteinase inhibitor, its use and DNA coding for this inhibitor
- *) Although these claims are partially directed to methods of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 95/02711

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-8809384	01-12-88	AT-T- 135049	15-03-96
		AU-B- 619750	06-02-92
		AU-B- 1939988	21-12-88
		DE-D- 3855078	11-04-96
		DE-T- 3855078	18-07-96
		EP-A- 0362259	11-04-90
		IL-A- 86476	25-01-94
		JP-T- 3501201	22-03-91
		US-A- 5432264	11-07-95
WO-A-9206111	16-04-92	AU-B- 659100	11-05-95
		AU-B- 8546091	28-04-92
		CA-A- 2092920	02-04-92
		CZ-A- 9300517	19-01-94
		EP-A- 0551329	21-07-93
		HU-A- 69955	28-09-95
		JP-T- 6501158	10-02-94
		SK-A- 26493	06-10-93
		PL-B- 168250	31-01-96
WO-A-9304082	04-03-93	NONE	
US-A-5124443	23-06-92	US-A- 5212297	18-05-93
EP-A-0511393	04-11-92	JP-A- 4258294	14-09-92
		JP-A- 4173798	22-06-92
		JP-B- 7119237	20-12-95
		AU-B- 648124	14-04-94
		AT-T- 140929	15-08-96
		AU-B- 5470194	24-03-94
		AU-B- 8846691	11-06-92
		CA-A- 2072375	09-05-92
		EP-A- 0687731	20-12-95
		WO-A- 9208736	29-05-92
		US-A- 5516656	14-05-96
WO-A-9523229	31-08-95	AU-B- 1817195	11-09-95